"Clinica Ematologica Centro Trapianti e Terapie Cellulari "Carlo Melzi" Azienda Ospedaliero Universitaria "
Welcome,         Profile    Billing    Logout  
 16 Trials 
17 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Zaja, Francesco
NCT02858258: ASCT After a Rituximab/Ibrutinib/Ara-c Containing iNduction in Generalized Mantle Cell Lymphoma

Checkmark [VIRTUAL] A phase II study of acalabrutinib in combination with R-CHOP chemotherapy prior to autologous stem cell transplantation in previously untreated mantle cell lymphoma
Recruiting
3
870
Europe
R-CHOP/R-DHAP, rituximab, CHOP, DHAP, Ibrutinib (Induction), Imbruvica, ASCT conditioning, THAM or BEAM, Ibrutinib (Maintenance)
Prof. Dr. M. Dreyling (co-chairman), Klinikum der Universitaet Muenchen
Mantle Cell Lymphoma
05/21
05/26
POLAR BEAR, NCT04332822 / 2018-003889-14: A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting
3
200
Europe
R-pola-mini-CHP, R-mini-CHOP
Nordic Lymphoma Group, Roche Pharma AG
DLBCL, Diffuse Large B Cell Lymphoma
02/23
02/26
NCT04168502: Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Recruiting
3
414
Europe
Glasdegib, Gemtuzumab Ozogamicin
Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia
04/23
04/27
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Calendar Jan 2023 - Dec 2023: From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Checkmark BRENTUXIMAB VEDOTIN IN COMBINATION WITH LENALIDOMIDE AND RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL: SAFETY AND EFFICACY RESULTS FROM THE SAFETY RUN-IN PERIOD OF THE PHASE 3 ECHELON-3 STUDY
Checkmark Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study.
Checkmark Phase I/Dose Expansion Trial of Brentuximab vedotin/Lenalidomide in Relapsed or Refractory Diffuse Large B-cell Lymphoma.
Checkmark Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ECHELON-3, Trial in Progress)
More
Recruiting
3
400
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
10/23
04/27
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Checkmark BRUIN CLL-321: A Phase 3 Open-Label, Randomized Study of Pirtobrutinib Versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in .…
Checkmark BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR'S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
Checkmark BRUIN CLL-321: A Phase 3 Open-label, Randomized Study of Pirtobrutinib versus Investigator’s Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (Trial in .…
Recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
01/24
06/24
FIL_PREVID, NCT04442412 / 2019-004474-26: Prephase Treatment With Prednisone +/- Vitamin D Supplementation Followed by Immunochemotherapy

Not yet recruiting
3
430
Europe
Vitamin D3 (Cholecalciferol), RCHOP o R-miniCHOP at standard doses
Fondazione Italiana Linfomi ONLUS, GRADE Onlus
Diffuse Large B-Cell Lymphoma, Elderly Patients
09/25
09/30
FIL_FOLL19, NCT05058404: Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma

Recruiting
3
602
Europe
Immunochemotherapy regimen: Rituximab-bendamustine (Arm A), R-Benda, R-bendamustine, Immunochemotherapy regimen: Rituximab-bendamustine (Arm B), Immunochemotherapy regimen: R-CHOP (Arm A), R-CHOP, Immunochemotherapy regimen: R-CHOP (Arm B), Immunochemotherapy regimen: G-bendamustine (Arm A), G-Benda, Immunochemotherapy regimen: G-bendamustine (Arm B), Immunochemotherapy regimen: G-CHOP (Arm A), G-CHOP, Immunochemotherapy regimen: G-CHOP (Arm B), Immunochemotherapy regimen: G-CVP (Arm A), G-CVP, Immunochemotherapy regimen: G-CVP (Arm B)
Fondazione Italiana Linfomi ONLUS
Follicular Lymphoma
07/28
07/30
NCT03552692 / 2017-004630-29: Use of Venetoclax as Single Agent in Patients With Relapsed/Refractory BCL-2 Positive Peripheral T Cell Lymphoma

Checkmark Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi.
Active, not recruiting
2
22
Europe
Venetoclax, ABT-199/GDC-0199
Fondazione Italiana Linfomi ONLUS
T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory
03/20
12/22
FIL_KLIMT, NCT03891355: Carfilzomib + Lenalidomide and Dexamethasone for BTK Inhibitors Relapsed-refractory or Intolerant MCL

Active, not recruiting
2
16
Europe
Carfilzomib, Lenalidomide, Dexamethasone
Fondazione Italiana Linfomi ONLUS
Mantle Cell Lymphoma
12/20
09/22
NCT04251065: Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH

Active, not recruiting
2
8
Europe
Daratumumab, Darzalex
Fondazione Italiana Linfomi ONLUS
Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma
12/21
11/22
NCT03731234: Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance

Recruiting
2
90
Europe
Ibrutinib, IMBRUVICA (commercial name)
Fondazione Italiana Linfomi ONLUS, Janssen-Cilag S.p.A.
DLBCL
02/23
02/25
MALIBU, NCT03697512: Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

Recruiting
2
175
Europe
Ibrutinib, Rituximab
International Extranodal Lymphoma Study Group (IELSG)
Marginal Zone Lymphoma, Nodal Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma
06/24
06/27
FIL_COLUMN, NCT05249959: Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Recruiting
2
56
Europe
Consolidation with ADCT-402 (loncastuximab tesirine) after salvage immunochemotherapy (R-BAC, Rituximab - Bendamustine, Ara-C))
Fondazione Italiana Linfomi ONLUS
Relapsed Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
02/25
02/27
NCT04454580: Hypomethylating Agents and Venetoclax in Newly Diagnosed Acute Myeloid Leukemia Patients Not Eligible for Intensive Chemotherapy

Recruiting
N/A
15
Europe
Venetoclax, Azacitidine, Decitabine
Ospedale Maggiore Di Trieste
Acute Myeloid Leukemia, Adult, Hypomethylating Agents, Venetoclax
09/20
09/20
ICI-RT-1, NCT04419441: Immune Checkpoint Inhibitors and Radiotherapy in Relapsed/Refractory Hodgkin Lymphoma

Recruiting
N/A
12
Europe
Immune checkpoint inhibitor, radiotherapy
Ospedale Maggiore Di Trieste
Hodgkin Lymphoma, Immune Checkpoint Inhibitor, Radiotherapy
09/20
09/20
NCT04352556: COVID19-hematological Malignancies: the Italian Hematology Alliance

Checkmark A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study.
Checkmark COVID-19 elicits an impaired antibody response against SARS-CoV-2 in patients with haematological malignancies.
Checkmark Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
Recruiting
N/A
250
Europe
Ospedale di Circolo - Fondazione Macchi
SARS-CoV-2 Infection, Hematological Malignancies
04/22
04/22
ITP0918, NCT03465020: Investigation on a Dynamic Cohort of Italian Patients With Active ITP

Recruiting
N/A
861
Europe
Observation
Gruppo Italiano Malattie EMatologiche dell'Adulto, Hematology Project Foundation
Idiopathic Thrombocytopenic Purpura
07/23
07/23

Download Options